(Q43233998)

16 November 2017

Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer (English)

1 reference

16 November 2017

1 reference

S Kulkarni

1

1 reference

16 November 2017

K B Reddy

2

1 reference

16 November 2017

F J Esteva

3

1 reference

16 November 2017

H C F Moore

4

1 reference

16 November 2017

G T Budd

5

1 reference

16 November 2017

R R Tubbs

6

1 reference

16 November 2017

language of work or name

English

0 references

publication date

30 November 2009

1 reference

16 November 2017

1 reference

16 November 2017

29

1 reference

16 November 2017

9

1 reference

16 November 2017

1339-1350

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.422

16 November 2017

0 references

cites work

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Regulation of the PTEN phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

The calpain cleavage sites in the epidermal growth factor receptor kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Calpain cleaves RhoA generating a dominant-negative form that inhibits integrin-induced actin filament assembly and cell spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Calpain mediates integrin-induced signaling at a point upstream of Rho family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Relevance of breast cancer cell lines as models for breast tumours: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Proteolysis of cortactin by calpain regulates membrane protrusion during cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

The calpain 1-alpha-actinin interaction. Resting complex between the calcium-dependent protease and its target in cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.422

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.422

1 reference

Dimensions Publication ID

16 November 2017

1020247025

0 references

Fatcat ID

release_t6icugzzavcslc4ugwgug2cxcy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/t6icugzzavcslc4ugwgug2cxcy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference